Cibus negotiations with EU moving forward is significant, says Canaccord

Canaccord said the Q4 results for Cibus (CBUS) were generally in line with management expectations considering the expected timeline to trait commercialization. With that said, the EU Council’s advancement of final negotiations on the legislative text governing the treatment of gene- editing technologies in the EU is significant. Canaccord maintains its Buy rating and $18 price target on Cibus shares.